Abstract
P53 is one of the most important tumour suppressor proteins. While its activity seems to be dispensable for normal proliferating cells, this protein is required to maintain genomic integrity after DNA damage. In response to cellular stress, the amount of p53 protein accumulates and fulfils its function as a transcription factor. Most of the genes that are regulated by p53 control progression through the cell cycle or initiate cell death. A large number of proteins have been identified in recent years that control the activity of this important tumour suppressor protein. These proteins regulate the turnover of p53, its association with co-repressor and co-activator proteins and target gene promoters or impinge on p53 oligomerisation. This review shall give an overview of our current knowledge on how the activity of the p53 protein is controlled.
Keywords: p53, DNA damage, phosphorylation, acetylation, ubiquitination, protein-protein interactions
Current Chemical Biology
Title: Regulation of p53 Activity
Volume: 4 Issue: 1
Author(s): Karen A. Boehme and Christine Blattner
Affiliation:
Keywords: p53, DNA damage, phosphorylation, acetylation, ubiquitination, protein-protein interactions
Abstract: P53 is one of the most important tumour suppressor proteins. While its activity seems to be dispensable for normal proliferating cells, this protein is required to maintain genomic integrity after DNA damage. In response to cellular stress, the amount of p53 protein accumulates and fulfils its function as a transcription factor. Most of the genes that are regulated by p53 control progression through the cell cycle or initiate cell death. A large number of proteins have been identified in recent years that control the activity of this important tumour suppressor protein. These proteins regulate the turnover of p53, its association with co-repressor and co-activator proteins and target gene promoters or impinge on p53 oligomerisation. This review shall give an overview of our current knowledge on how the activity of the p53 protein is controlled.
Export Options
About this article
Cite this article as:
Boehme A. Karen and Blattner Christine, Regulation of p53 Activity, Current Chemical Biology 2010; 4 (1) . https://dx.doi.org/10.2174/2212796811004010001
DOI https://dx.doi.org/10.2174/2212796811004010001 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Invasion Induction as a Therapeutic Strategy for the Treatment of Cancer
Current Cancer Drug Targets Polyglandular Autoimmune Syndromes
Current Immunology Reviews (Discontinued) Inhibitory Potential of Dietary Nutraceuticals on Cellular PI3K/Akt Signaling: Implications in Cancer Prevention and Therapy
Current Topics in Medicinal Chemistry Arsenic Immunotoxicity and Immunomodulation by Phytochemicals: Potential Relations to Develop Chemopreventive Approaches
Recent Patents on Inflammation & Allergy Drug Discovery Betulinic Acid as a Potent and Complex Antitumor Phytochemical: A Minireview
Anti-Cancer Agents in Medicinal Chemistry Understanding the Interaction Between Human Serum Albumin and Anti-Bacterial/ Anti-Cancer Compounds
Current Pharmaceutical Design Paclitaxel Nanoparticles Induce Apoptosis and Regulate TXR1, CYP3A4 and CYP2C8 in Breast Cancer and Hepatoma Cells
Anti-Cancer Agents in Medicinal Chemistry Current and Emerging Strategies in Bladder Cancer
Anti-Cancer Agents in Medicinal Chemistry Evaluating Potential P-gp Substrates: Main Aspects to Choose the Adequate Permeability Model for Assessing Gastrointestinal Drug Absorption
Mini-Reviews in Medicinal Chemistry GnRH Agonists and Antagonists in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Strategies for Efficient Lead Structure Discovery from Natural Products
Current Medicinal Chemistry Update on Hsp90 Inhibitors in Clinical Trial
Current Topics in Medicinal Chemistry Organ- and Cell-Type Specific Delivery of Kinase Inhibitors: A Novel Approach in the Development of Targeted Drugs
Current Molecular Pharmacology Angiogenic and Anti-Angiogenic Therapy for Gastrointestinal Ulcers: New Challenges for Rational Therapeutic Predictions and Drug Design
Current Pharmaceutical Design Recent Advances of Kinesin Motor Inhibitors and their Clinical Progress
Reviews on Recent Clinical Trials Oxidative Phosphorylation as a Target to Arrest Malignant Neoplasias
Current Medicinal Chemistry New Perspectives for Melanoma Immunotherapy: Role of IL-12
Current Molecular Medicine Meet Our Editorial Board Member:
Applied Clinical Research, Clinical Trials and Regulatory Affairs Mesenchymal Stem Cells for Anti-Cancer Drug Delivery
Recent Patents on Anti-Cancer Drug Discovery Glutathione for Hepatotoxicity in Patients with Liver Cirrhosis and Advanced Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy
Clinical Cancer Drugs